Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients (PASART-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02575066
Recruitment Status : Terminated (stopping rule)
First Posted : October 14, 2015
Last Update Posted : June 27, 2019
Royal Marsden NHS Foundation Trust
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:

Radiotherapy (RT) alone is able to induce a clinically significant effect with a variable pathologic response (a pathological complete remission, pCR, defined as ≥ 95%, or ≤ 5% remaining visible tumour cells) in only about 10% of cases. A prior phase I study (PASART-1; NCT01985295) suggested that 25 x 2 Gy preoperative RT in combination with once daily 800mg oral pazopanib is feasible, while inducing tissue replacing tumor that can consist of fibrosis and necrosis in 40% of thus treated patients.

During this study, the interim analysis showed that the combination treatment of preoperative radiation with orally pazopanib is more effective than was anticipated. For this reason, the pazopanib dose of 800 mg once daily is maintained but the RT dose is reduced to 18x2Gy instead of 25x2Gy. Predominant aim of this RT dose reduction is lowering the wound complication risk after preoperative radiotherapy.

Condition or disease Intervention/treatment Phase
Sarcoma Soft Tissue Sarcomas Radiation: external beam radiotherapy Drug: pazopanib Phase 2

Detailed Description:

Patients of the first part of the study received radiotherapy (25x2Gy) and pazopanib (QD 800 mg).

Patients of the second part of the study received/ will receive radiotherapy (18x2Gy) and pazopanib (QD 800 mg).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)
Actual Study Start Date : March 17, 2016
Actual Primary Completion Date : March 20, 2019
Actual Study Completion Date : March 20, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Pazopanib

Arm Intervention/treatment
radiotherapy combined with pazopanib
patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
Radiation: external beam radiotherapy
external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
Other Name: radiotherapy

Drug: pazopanib
pazopanib QD 800 mg

Primary Outcome Measures :
  1. pathological near complete remission of the resected specimen which has been treated with radiotherapy [ Time Frame: 6 weeks post treatment ]
    Proportion of patients with resection specimens demonstrating induction of a pathological (near) complete remission (≥ 95% tumor regression). Pathological (near) complete remission is defined as ≥ 95% replacement of tumor with other tissue, usually fibrosis and) in the resection specimen post combined pazopanib and radiotherapy treatment

Secondary Outcome Measures :
  1. Incidence toxicities measured by NCI-CTCAE v4.0 (radiotherapy alone, pazopanib alone or both) measured from start of treatment until 6 weeks post-treatment [ Time Frame: during treatment and up to 6 weeks post treatment ]
  2. Rate of response as measured by RECIST v 1.1 at 4 weeks after completing radiotherapy [ Time Frame: 4 weeks post treatment ]
  3. Incidence of acute post-operative wound complications up to 3 weeks (+/- 1 week) after surgery as defined in section 6.1.3 and reference 29 (see also appendix XII) [ Time Frame: up to 3 weeks post surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area, for which the standard treatment is a combination of and radiotherapy and surgery(deep seated and/or > 5cm according to the RECIST 1.1 criteria and/or an anticipated close resection margin and/or grade II/III according to the WHO definition)
  • Age ≥ 18 years
  • WHO performance status of ≤ 1
  • Able and willing to undergo blood sampling for PK and PD analysis
  • Able to swallow and retain oral medication
  • Able and willing to undergo MRI scanning
  • Able and willing to undergo tumor biopsies
  • Adequate organ functions as described by the laboratory findings in the table 1. For thyroid function, the T4 and TSH values must be within normal values of the range of the participating centers
  • Written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.

Exclusion Criteria

  • Prior malignancies; except another malignancy and disease-free for ≥ 5 years, or completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma.
  • Patients with recurrent sarcomas (even without prior radiotherapy)
  • Ewing sarcoma and other PNET family tumors, rhabdomyosarcomas (both pediatric and adult), osteosarcomas
  • Clinically significant gastrointestinal abnormalities which might interfere with oral dosing diagnosed
  • Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg]
  • Unstable or serious concurrent condition (e.g., active infection requiring systemic therapy)
  • Prolongation of corrected QT interval (QTc) > 480 msecs on ECG
  • History of any of more of the following cardiovascular conditions within the past 6 months:
  • Cardiac angioplasty or stenting
  • Myocardial infarction
  • Unstable angina
  • Symptomatic peripheral vascular disease
  • Coronary artery by-pass graft surgery
  • Class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA)
  • History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
  • Macroscopic hematuria
  • Hemoptysis that is clinically relevant within 4 weeks of first dose of pazopanib
  • Evidence of active bleeding or bleeding diathesis
  • Prior major surgery or trauma within 28 days prior to first dose of study medication and/or presence of any non-healing wound, fracture, or ulcer
  • Chemotherapy or radiation therapy within 2 weeks prior to the first dose of study medication
  • Biological therapy or treatment with an investigational agent within 28 days or five half-lives, whichever is longer prior to the first dose of study medication
  • Prohibited medications listed in the protocol for 14 days or five half-lives of a drug (whichever is longer) prior to visit 1 and for the duration of the study
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02575066

Layout table for location information
Antoni van Leeuwenhoek
Amsterdam, Netherlands, 1066CX
Leids Universitair Medisch Centrum
Leiden, Netherlands, 2333 ZA
United Kingdom
Royal Marsden Hospital
London, United Kingdom, SW3 6JJ
Sponsors and Collaborators
The Netherlands Cancer Institute
Royal Marsden NHS Foundation Trust
Layout table for investigator information
Principal Investigator: Rick Haas, MD, PhD The Netherlands Cancer Institute
Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute Identifier: NCT02575066    
Other Study ID Numbers: M15PAS
DSSG02 ( Other Identifier: Dutch Sarcoma Study Group )
First Posted: October 14, 2015    Key Record Dates
Last Update Posted: June 27, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Netherlands Cancer Institute:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type